Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes Insipidus II: Pathophysiology01:22

Diabetes Insipidus II: Pathophysiology

Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Castleman's disease in the rheumatological practice.

Zeitschrift fur Rheumatologie·2024
Same author

[Castleman's disease in the rheumatological practice].

Zeitschrift fur Rheumatologie·2023
Same author

[Autoinflammatory diseases].

Zeitschrift fur Rheumatologie·2020
Same author

[Local and systemic light chain amyloidosis in patients with rheumatic diseases].

Zeitschrift fur Rheumatologie·2020
Same author

[Autologous hematopoietic stem cell transplantation for systemic sclerosis : Position statement of the stem cell therapy working party of the German Society of Rheumatology].

Zeitschrift fur Rheumatologie·2020
Same author

[Autoinflammatory syndromes and AA amyloidosis].

Zeitschrift fur Rheumatologie·2020
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Related Experiment Video

Updated: May 28, 2026

A Caenorhabditis elegans Model System for Amylopathy Study
10:33

A Caenorhabditis elegans Model System for Amylopathy Study

Published on: May 17, 2013

[Systemic amyloidoses].

S Schönland1, N Blank, A V Kristen

  • 1Amyloidose-Zentrum, Universitätsklinikum Heidelberg, Heidelberg, Deutschland. stefan.schoenland@med.uni-heidelberg.de

Der Internist
|October 29, 2011
PubMed
Summary
This summary is machine-generated.

Amyloidoses are rare protein folding disorders where abnormal protein aggregates damage organs. Early diagnosis and treatment, like chemotherapy or transplantation, are crucial for managing systemic amyloidosis and preventing organ damage.

More Related Videos

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa
07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

Related Experiment Videos

Last Updated: May 28, 2026

A Caenorhabditis elegans Model System for Amylopathy Study
10:33

A Caenorhabditis elegans Model System for Amylopathy Study

Published on: May 17, 2013

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa
07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

Area of Science:

  • Biochemistry and Molecular Biology
  • Pathology
  • Genetics

Context:

  • Amyloidoses represent a group of rare protein misfolding diseases.
  • These disorders involve the deposition of insoluble protein aggregates in tissues.
  • They can manifest in localized or systemic forms, with systemic types posing life-threatening risks.

Purpose:

  • To elucidate the nature of protein misfolding in amyloidosis.
  • To highlight the systemic implications and associated diseases.
  • To emphasize the critical need for early diagnosis and effective treatment strategies.

Summary:

  • Amyloidoses result from protein conformational changes leading to insoluble fibrillar aggregate deposition.
  • Systemic amyloidoses are severe complications linked to monoclonal gammopathy, chronic inflammation, or hereditary conditions.
  • Effective treatments focus on reducing the amyloid precursor protein via chemotherapy, anti-inflammatory therapies, or liver transplantation.

Impact:

  • Early diagnosis is vital for effective patient management and preventing progressive organ dysfunction.
  • Understanding protein folding disorders improves therapeutic approaches.
  • Timely intervention can significantly alter patient outcomes in systemic amyloidosis.